Oncology
Myelofibrosis
Conference Reporter® Podcast: Risk Assessment and Prognosis in Myelofibrosis
The overall survival of patients with myelofibrosis is significantly impacted by numerous clinical factors at diagnosis. Recent information discussed at the 2026 ASCO Annual Meeting indicates that integrating clinical factors with molecular data provides a more accurate risk assessment and prognosis for myelofibrosis, which can lead to more personalized treatment strategies. Raajit K. Rampal, MD, PhD, covers these topics in today’s podcast.
Following these presentations, featured expert Raajit K. Rampal, MD, PhD, was interviewed by Conference Reporter Associate Editor-in-Chief Rick Davis, MS, RPh. Clinical perspectives from Dr Rampal on these findings are presented here.
Abdalla A, Thukral J, Jajja S, et al. Impact of erythrocytosis on overall survival, thrombotic events, and risk of transformation to AML in patients with myelofibrosis [abstract e18637] [session: Publication only: hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Chandani KU, Thukral J, Shah R, et al. Impact of anemia on real-world outcomes in myelofibrosis: a propensity-matched analysis [abstract e18609] [session: Publication only: hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Chandani KU, Thukral J, Shah R, et al. Impact of leukocytosis on outcomes in patients with myelofibrosis: a propensity-matched analysis [abstract e18608] [session: Publication only: hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.
